These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

731 related articles for article (PubMed ID: 30069853)

  • 1. Induced Pluripotent Stem Cells and Induced Pluripotent Cancer Cells in Cancer Disease Modeling.
    Zhu D; Kong CSL; Gingold JA; Zhao R; Lee DF
    Adv Exp Med Biol; 2018; 1119():169-183. PubMed ID: 30069853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of induced pluripotent stem cell technology.
    Zhou H; Ding S
    Curr Opin Hematol; 2010 Jul; 17(4):276-80. PubMed ID: 20442654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
    Liu Y; Deng W
    Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications.
    Omole AE; Fakoya AOJ
    PeerJ; 2018; 6():e4370. PubMed ID: 29770269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current progress and potential practical application for human pluripotent stem cells.
    Philonenko ES; Shutova MV; Chestkov IV; Lagarkova MA; Kiselev SL
    Int Rev Cell Mol Biol; 2011; 292():153-96. PubMed ID: 22078961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induced pluripotent stem cells (iPSCs)--a new era of reprogramming.
    Kang L; Kou Z; Zhang Y; Gao S
    J Genet Genomics; 2010 Jul; 37(7):415-21. PubMed ID: 20659705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress made in the reprogramming field: new factors, new strategies and a new outlook.
    Hussein SM; Nagy AA
    Curr Opin Genet Dev; 2012 Oct; 22(5):435-43. PubMed ID: 22959308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration-free reprogramming of human somatic cells to induced pluripotent stem cells (iPSCs) without viral vectors, recombinant DNA, and genetic modification.
    Heng BC; Fussenegger M
    Methods Mol Biol; 2014; 1151():75-94. PubMed ID: 24838880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering personalized neural tissue by combining induced pluripotent stem cells with fibrin scaffolds.
    Montgomery A; Wong A; Gabers N; Willerth SM
    Biomater Sci; 2015 Feb; 3(2):401-13. PubMed ID: 26218131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of Naivetropic Induced Pluripotent Stem Cells from Parkinson's Disease Patients for High-Efficiency Genetic Manipulation and Disease Modeling.
    Hu Z; Pu J; Jiang H; Zhong P; Qiu J; Li F; Wang X; Zhang B; Yan Z; Feng J
    Stem Cells Dev; 2015 Nov; 24(21):2591-604. PubMed ID: 26218671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induced pluripotent stem cell modeling of malignant hematopoiesis.
    Chao MP; Majeti R
    Exp Hematol; 2019 Mar; 71():68-76. PubMed ID: 30659850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equine Induced Pluripotent Stem Cell Culture.
    Falk J; Donadeu FX
    Methods Mol Biol; 2024; 2749():175-184. PubMed ID: 38133784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induced pluripotent stem cells and their use in cardiac and neural regenerative medicine.
    Skalova S; Svadlakova T; Shaikh Qureshi WM; Dev K; Mokry J
    Int J Mol Sci; 2015 Feb; 16(2):4043-67. PubMed ID: 25689424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-derived induced pluripotent stem cells for models of cancer and cancer stem cell research.
    Chao HM; Chern E
    J Formos Med Assoc; 2018 Dec; 117(12):1046-1057. PubMed ID: 30172452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome editing of human pluripotent stem cells to generate human cellular disease models.
    Musunuru K
    Dis Model Mech; 2013 Jul; 6(4):896-904. PubMed ID: 23751357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial and metabolic remodeling during reprogramming and differentiation of the reprogrammed cells.
    Choi HW; Kim JH; Chung MK; Hong YJ; Jang HS; Seo BJ; Jung TH; Kim JS; Chung HM; Byun SJ; Han SG; Seo HG; Do JT
    Stem Cells Dev; 2015 Jun; 24(11):1366-73. PubMed ID: 25590788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pluripotent stem cell derivation and differentiation toward cardiac muscle: novel techniques and advances in patent literature.
    Quattrocelli M; Thorrez L; Sampaolesi M
    Recent Pat Drug Deliv Formul; 2013 Apr; 7(1):18-28. PubMed ID: 22974171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the application of induced pluripotent stem cells in pediatric diseases.
    Tian ZC; Yin XJ
    Yi Chuan; 2023 Jan; 45(1):42-51. PubMed ID: 36927637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis in Porcine Pluripotent Cells: From ICM to iPSCs.
    Kim E; Hyun SH
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27626414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoskeletal Expression and Remodeling in Pluripotent Stem Cells.
    Boraas LC; Guidry JB; Pineda ET; Ahsan T
    PLoS One; 2016; 11(1):e0145084. PubMed ID: 26771179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.